Previous 10 | Next 10 |
home / stock / mmed:cc / mmed:cc news
– Company positioned for key MM-120 Phase 2b data readout in GAD and Phase 2a data readout in ADHD in late 2023 – – Company to initiate first clinical trial of MM-402 in 2023 – – Cash and cash equivalents of $142.1 million at December 31, 202...
After decades of federal prohibition prevented the research and medical use of psychedelic drugs, the U.S. Department of Veteran Affairs is now considering opening the door to psychedelic treatments for veterans. Research in the 1960s first revealed that psychedelics had therapeutic propert...
Ayahuasca is one of the several psychedelics that have exhibited significant potential as treatment for mental health disorders . Research has revealed that psychedelics such as ayahuasca are capable of alleviating the symptoms of conditions, including treatment-resistant depression and post-t...
A surge of psychedelic research over the past decade has revealed what some scientists in the late 1950s and early 19960s suspected: hallucinogens have protective mental health properties. Groundbreaking research in recent years has shown that classic psychedelics such as DMT, psilocybin, ketam...
At the start of the year, the Colorado Department of Regulatory Agencies (DORA) began searching for individuals to join an advisory board that would be responsible for informing on psychedelic policy. As part of those efforts, DORA promoted a web page where interested professionals could fill...
During a recent webinar , an official of the Department of Veterans Affairs revealed that the agency was closely observing psychedelics policy and research as the reform wave continued to sweep across states in the country. Dr. Ilse Wiechers, deputy executive director of the Office of Mental He...
Palm Beach, FL – January 26, 2023 – FinancialNewsMedia.com News Commentary – Even during the recent global supply chain problems, certain markets have continued to show growth. The psychedelic drugs markets is one of these continually expanding markets. Psychedeli...
With at least one in five Americans said to experience mental illness at least once a year and more than 2.7 million youth suffering from severe major depression, interest in safe and effective mental health treatments is at an all-time high. Initial research has uncovered that psychedelics s...
Psychedelics have become increasingly popular, with more studies finding that the substances may have therapeutic benefits for a range of mental health disorders. While this is positive, their adoption into mainstream media also increases the risk of teens consuming these drugs in the name of e...
MindMed Provides Corporate Update and 2023 Outlook Canada NewsWire - Company positioned for key MM-120 Phase 2b data readout in GAD and Phase 2a data readout in ADHD in late 2023 - Company to initiate first clinical trial of MM-402 in 2023 - Cash runway to ...
News, Short Squeeze, Breakout and More Instantly...
Hallucinogenic persistent perception disorder (HPPD) is an intoxication disorder caused by psychedelic drugs that encompasses a range of visual disturbances that occur in different time frames. The disorder also causes extreme anxiety as well as out-of-body sensations and is marked by shame as w...
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present posters describing the...
All Common shares will remain listed on Nasdaq Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today ...